5-Fluorouracil increases the number and complexity of premature complexes in the heart: A prospective study using ambulatory ECG monitoring

International Journal of Clinical Practice

Volumn 61, Issue 5, 2007, Pages 795-801

  Yilmaz, U ^a   Oztop, I ^a   Ciloglu, A ^a   Okan, T ^a   Tekin, U ^a   Yaren, A ^b   Somali, I ^a   Alacacioglu, A ^a   Kirimli, O ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; HEART ENZYME; ORAL ANTIDIABETIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; AMBULATORY MONITORING; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES MELLITUS; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; ESOPHAGUS CANCER; FEMALE; HEART RATE; HEART RHYTHM; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HUMAN; HYPERTENSION; LIVER CANCER; LOADING DRUG DOSE; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE CYCLE TREATMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; ST SEGMENT; STOMACH CANCER; SUPRAVENTRICULAR PREMATURE BEAT; SYMPTOM; THORAX PAIN;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARDIAC COMPLEXES, PREMATURE; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 34247113188     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01323.x     Document Type: Article

References (29)

1. Skibber JM, Minsky BD, Hoff PM. Cancer of the colon. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology (4th edn). Philadelphia, PA: Lippincott, 1997: 1216-71.
2. Lokich JJ, Ahlgren JD, Gullo JJ. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425-32.
3. De Gramont A, Bosset J-F, Milan C et al. A randomized trial comparing monthly low-dose leuconerin-5-fluorouracil bolus with bimonthly high-dose leucoverin-5-fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study (FFCD, GERCOD, SNFMI). J Clin Oncol 1997; 15: 808-15.
4. Forni M, Malet-Martino MC, Jaillais P et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795-801.
5. Akhtar S, Salim K, Bano Z. Symptomatic cardiotoxicity with highdose 5-fluorouracil infusion: a prospective study. Oncology 1993; 50: 441-4.
6. Meyer C, Anton Calis K, Burke L, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17: 729-36.
7. Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68: 505-10.
8. Schober C, Papageorgiou E, Harstrick A et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993; 72: 2242-7.
9. Tsavaris N, Kosmas C, Vadiaka M et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients. Med Sci Monit 2002; 8: 151-7.
10. Oztop I, Gencer M, Okan T et al. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-Fluorouracil/Folinic acid treatment by echocardiography, plasma troponin I level, Q-T interval and dispersion in patients with gastrointestinal system cancers. Jpn, J Clin Oncol 2004; 34: 262-8.
11. Roden DM. Drug therapy: drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22.
12. Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation 1971; 44: 130-42.
13. Rezkalla S, Kloner RA, Ensley J et al. Continuous ambulatory monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7: 509-14.
14. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine 3 receptor antagonists. Ann Pharmacother 2003; 9: 1276-86.
15. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol 1990, 1: 409-14.
16. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28: 374-8.
17. Le Maire L, Malet-Martino MC, Martino R et al. The Tris formulation of fluorouracil is more cardiotoxic than the sodium salt formulations. Oncol Rep 1994; 1: 173-4.
18. Levillain R. Lesion cardiague observee en microscopie optique chez le rat wistar apres ingestion de 5-fluorouracil. J Med Besancon 1972; 8: 37-44.
19. Hiss RG, Lamb LE. Electrocardiographic findings in 122043 individuals. Circulation 1962; 25: 947-61.
20. Kennedy HL, Whitlock JA, Sprague MK, Kennedy LJ, Buckingham TA, Goldberg RJ. Long term follow up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. New Engl J Med 1985; 312: 193-7.
21. Kostis JB, Allen R, Berkson DM et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. SHEP Cooperative Research Group. Am Heart J 1994; 127: 112-21.
22. Inoue T, Koumatsu K, Ito M, Arita M, Saikawa T. Heart ratedependent alteration of the frequency and coupling interval of ventricular arrhythmias as measured by 24-hour ECG monitoring. Jpn Circ J 1991; 55: 942-50.
23. Myerburg RJ, Kessler KM, Mallon SM et al. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med 1992; 326: 1451-5.
24. Chakko CS, Gheorghiade M. Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. Am Heart J 1985; 109: 497-504.
25. ACC/AHA Guidelines for Ambulatory Electrocardiography. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 1999; 34: 912-48.
26. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 25: 1041-7.
27. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
28. Oztop I, Yilmaz U, Yavuzsen T et al. Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas. Chemotherapy 2004; 50: 127-32.
29. Van Cutsem E, Hoff PM, Blum JL et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002, 13: 484-5.